What Happened to CRISPR Gene Editing?
CRISPR gene editing, a revolutionary technology derived from a bacterial immune system, has rapidly transformed biomedical research and clinical medicine. After its initial development as a precise gene-editing tool in 2012, it achieved its first regulatory approvals in late 2023 for treating sickle cell disease and beta-thalassemia, marking a new era for genetic therapies. As of early 2026, advancements continue with new editing modalities like base and prime editing, personalized treatments, and expanded applications in cancer, autoimmune diseases, and agriculture.
Quick Answer
CRISPR gene editing has evolved from a groundbreaking research tool into a clinically approved therapeutic technology. Following the landmark regulatory approvals of Casgevy in late 2023 for sickle cell disease and beta-thalassemia, the field is rapidly expanding. Recent developments in 2025 and early 2026 include the first human clinical data for prime editing, the administration of personalized CRISPR therapies for ultra-rare diseases, and new regulatory pathways from the FDA to accelerate such bespoke treatments. Researchers are also exploring 'gentler' forms of gene editing that don't cut DNA, and applying CRISPR to enhance cancer therapies and agricultural resilience.
📊Key Facts
📅Complete Timeline16 events
Discovery of CRISPR Repeats
Yoshizumi Ishino and his team at Osaka University first observed unusual repeating DNA sequences in E. coli, later named CRISPR. [3, 8]
CRISPR's Immune Function Hypothesized & Cas9 Described
Francisco Mojica correctly hypothesized that CRISPR acts as an adaptive immune system in bacteria. Independently, Alexander Bolotin's group described the Cas9 protein, predicted to have nuclease activity. [2, 3, 6]
Discovery of tracrRNA
Emmanuelle Charpentier's group discovered trans-activating CRISPR RNA (tracrRNA), a crucial component that forms a duplex with crRNA to guide Cas9. [2, 3, 24]
CRISPR-Cas9 Reprogrammed for Gene Editing
Jennifer Doudna and Emmanuelle Charpentier published their landmark paper demonstrating that CRISPR-Cas9 could be simplified and reprogrammed to precisely cut DNA in a test tube. [2, 6, 24]
First Application in Human Cells
Feng Zhang's lab and George Church's lab independently published methods for using CRISPR-Cas9 to edit genes in human and mouse cells. [2, 6]
First Human CRISPR Clinical Trial (China)
Chinese scientists conducted the world's first human clinical trial using CRISPR-edited T cells to treat a patient with aggressive lung cancer. [13, 22, 34]
First US Human CRISPR Clinical Trial
The first U.S. human trial using CRISPR to treat cancer began, modifying immune cells to attack tumors. [15]
Development of Prime Editing
David Liu's lab developed prime editing, a 'search and replace' gene-editing technology that can make precise changes to DNA without creating double-stranded breaks. [5, 7]
Nobel Prize in Chemistry Awarded
Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for their development of a method for genome editing. [3, 6, 8, 24]
First FDA Approval of CRISPR Therapy (Casgevy)
The U.S. FDA approved Casgevy (exagamglogene autotemcel), the first CRISPR/Cas9-based gene therapy, for the treatment of sickle cell disease in patients 12 years and older. [9, 18, 26, 30]
First In-Human Trial of CRISPR for HIV
The first in-human trial of a CRISPR-Cas system delivered by adeno-associated virus 9 gene therapy to treat HIV showed promising safety results and targeted the intended DNA. [32]
First Human Clinical Data for Prime Editing
Prime Medicine announced positive results from treating a patient with chronic granulomatous disease (CGD), marking the first-ever clinical data showing the efficacy and safety of prime editing in humans. [1, 4]
First Personalized CRISPR Treatment Administered to Infant
Baby KJ became the world's first patient treated with a bespoke in vivo CRISPR-based therapy for CPS1 deficiency, developed and delivered in just six months. [1, 11]
CRISPR Breakthrough: Gene Activation Without DNA Cuts
Scientists at UNSW Sydney developed a new CRISPR technology that can turn genes on by removing chemical tags (epigenome editing) without cutting DNA, offering a safer approach for conditions like sickle cell disease. [14]
FDA 'Plausible Mechanism Pathway' for Rare Diseases
The US FDA issued draft guidance on a 'plausible mechanism pathway' to accelerate the development and approval of highly specific, personalized therapies, including genome editing, for ultra-rare diseases. [11, 12, 25]
CRISPR Platform for Leukemia Drivers in Patient Cells
Penn Medicine and Children's Hospital of Philadelphia launched a new CRISPR-based platform to directly identify genes and regulatory elements driving acute myeloid leukemia in patient cells, aiming for personalized cancer treatments. [31]
🔍Deep Dive Analysis
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing originated from the discovery of unusual DNA sequences in bacteria in 1987 by Yoshizumi Ishino and his team. [3, 8] Over the next two decades, researchers, notably Francisco Mojica, elucidated that these sequences, along with associated (Cas) proteins, formed an adaptive immune system in prokaryotes, allowing them to defend against viral invaders by cutting their DNA. [2, 3, 6]
The pivotal breakthrough came in 2012 when Jennifer Doudna and Emmanuelle Charpentier demonstrated that the CRISPR-Cas9 system could be reprogrammed to precisely cut any desired DNA sequence, effectively creating 'genetic scissors.' [2, 6, 8, 24] This discovery, which earned them the Nobel Prize in Chemistry in 2020, [3, 6, 8, 24] quickly led to its application in human cells by groups including Feng Zhang and George Church in 2013. [2, 6] The simplicity, efficiency, and precision of CRISPR-Cas9 rapidly propelled it to the forefront of genome editing, with Science magazine naming it the 'Breakthrough of the Year' in 2015. [8]
Early clinical trials began in 2016 in China for lung cancer, demonstrating the feasibility and safety of CRISPR-edited T cells. [13, 22, 34] The first U.S. human trials followed in 2018, targeting various cancers. [15] A significant turning point arrived in late 2023 with the first regulatory approvals of a CRISPR-based therapy, Casgevy (exagamglogene autotemcel), developed by CRISPR Therapeutics and Vertex Pharmaceuticals. It received approval from the UK MHRA, US FDA, and European Medicines Agency (EMA) for treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TBT) in patients aged 12 and older. [9, 18, 26, 27, 30] These approvals validated CRISPR as a curative approach for severe genetic blood disorders.
Since these landmark approvals, the field has seen rapid diversification and refinement. David Liu's development of base editing (2016) and prime editing (2019) offered more precise ways to alter single DNA bases or short sequences without creating double-stranded breaks, potentially reducing off-target effects and improving safety. [5, 7] In May 2025, Prime Medicine announced the first human clinical data for prime editing, showing efficacy and safety in a patient with chronic granulomatous disease (CGD). [1, 4] Also in May 2025, a remarkable medical breakthrough saw the first personalized in vivo CRISPR therapy administered to an infant, Baby KJ, for CPS1 deficiency, developed and delivered in just six months. [1, 11]
As of early 2026, CRISPR continues to advance across multiple fronts. In January 2026, a new CRISPR breakthrough demonstrated the ability to turn genes on without cutting DNA by removing chemical tags, offering a gentler approach for conditions like sickle cell disease. [14] In February 2026, Penn Medicine launched a CRISPR-based platform to pinpoint drivers of acute myeloid leukemia directly in patient cells, aiming for more personalized cancer therapies. [31] The US FDA also issued draft guidance in February 2026 on a 'plausible mechanism pathway' to streamline the approval of highly specific, personalized therapies for ultra-rare diseases, explicitly mentioning genome editing. [11, 12, 25] The global CRISPR-based gene editing market was valued at USD 7.25 billion in 2025 and is projected to reach around USD 28.77 billion by 2035, reflecting significant ongoing investment and expansion. [10] Ethical considerations, including equitable access and the implications of germline editing, remain central to the ongoing discourse surrounding CRISPR's future. [3, 21, 23]